MX2022013698A - Dispositivos de administracion transdermica de farmacos que contienen psilocibina, dietilamida de acido lisergico o microprotuberancias recubiertas con 3,4-metilendioximetanfetamina. - Google Patents
Dispositivos de administracion transdermica de farmacos que contienen psilocibina, dietilamida de acido lisergico o microprotuberancias recubiertas con 3,4-metilendioximetanfetamina.Info
- Publication number
- MX2022013698A MX2022013698A MX2022013698A MX2022013698A MX2022013698A MX 2022013698 A MX2022013698 A MX 2022013698A MX 2022013698 A MX2022013698 A MX 2022013698A MX 2022013698 A MX2022013698 A MX 2022013698A MX 2022013698 A MX2022013698 A MX 2022013698A
- Authority
- MX
- Mexico
- Prior art keywords
- psilocybin
- methylenedioxymethamphetamine
- drug delivery
- delivery devices
- transdermal drug
- Prior art date
Links
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 title abstract 3
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 title abstract 3
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 title abstract 3
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 title abstract 3
- 229950002454 lysergide Drugs 0.000 title 1
- 238000013271 transdermal drug delivery Methods 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En el presente documento se desvelan composiciones, dispositivos y métodos que emplean concentraciones terapéuticas de psilocibina, LSD o MDMA para el tratamiento de ciertas condiciones de salud, incluyendo depresión, ansiedad, trastorno de estrés postraumático, migraña y cefalea en racimos. También se describen métodos y aparatos para administrar psilocibina, LSD o MDMA por administración intracutánea a través de la administración de microagujas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063018759P | 2020-05-01 | 2020-05-01 | |
PCT/US2021/030437 WO2021222885A1 (en) | 2020-05-01 | 2021-05-03 | Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013698A true MX2022013698A (es) | 2023-01-16 |
Family
ID=78374014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013698A MX2022013698A (es) | 2020-05-01 | 2021-05-03 | Dispositivos de administracion transdermica de farmacos que contienen psilocibina, dietilamida de acido lisergico o microprotuberancias recubiertas con 3,4-metilendioximetanfetamina. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230210762A1 (es) |
EP (1) | EP4142693A1 (es) |
JP (1) | JP2023526776A (es) |
CN (1) | CN115484930A (es) |
AU (1) | AU2021264077A1 (es) |
BR (1) | BR112022021831A2 (es) |
CA (1) | CA3177297A1 (es) |
IL (1) | IL297669A (es) |
MX (1) | MX2022013698A (es) |
WO (1) | WO2021222885A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4038192A4 (en) | 2019-10-01 | 2023-11-01 | Empyrean Neuroscience, Inc. | GENETIC MANIPULATION OF MUSHROOMS TO MODULATE TRYPTAMINE EXPRESSION |
KR20230024378A (ko) | 2020-06-12 | 2023-02-20 | 벡클리 싸이테크 리미티드 | 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 |
WO2022235500A1 (en) * | 2021-05-03 | 2022-11-10 | Mind Medicine, Inc. | Psychedelics for treatment of pain |
WO2023012691A1 (en) * | 2021-08-03 | 2023-02-09 | Pike Therapeutics, Inc. | Transdermal micro-dosing delivery of pharmaceutical agents |
WO2023108165A2 (en) * | 2021-12-10 | 2023-06-15 | GATC Health Corp | Methods of treating addiction and neurological disorders |
WO2023111544A2 (en) * | 2021-12-13 | 2023-06-22 | Beckley Psytech Limited | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
WO2023250247A2 (en) * | 2022-06-25 | 2023-12-28 | Mind Medicine, Inc. | R-mdma crystal forms |
GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3332799A1 (en) * | 2011-04-22 | 2018-06-13 | Radius Health, Inc. | Method of drug delivery for pth, pthrp and related peptides |
EP3416618A1 (en) * | 2016-02-19 | 2018-12-26 | ZP Opco, Inc. | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines |
US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
US11660264B2 (en) * | 2017-08-23 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
-
2021
- 2021-05-03 AU AU2021264077A patent/AU2021264077A1/en active Pending
- 2021-05-03 US US17/997,094 patent/US20230210762A1/en active Pending
- 2021-05-03 EP EP21796794.2A patent/EP4142693A1/en not_active Withdrawn
- 2021-05-03 BR BR112022021831A patent/BR112022021831A2/pt not_active Application Discontinuation
- 2021-05-03 CA CA3177297A patent/CA3177297A1/en active Pending
- 2021-05-03 MX MX2022013698A patent/MX2022013698A/es unknown
- 2021-05-03 CN CN202180031657.2A patent/CN115484930A/zh active Pending
- 2021-05-03 IL IL297669A patent/IL297669A/en unknown
- 2021-05-03 JP JP2022565597A patent/JP2023526776A/ja active Pending
- 2021-05-03 WO PCT/US2021/030437 patent/WO2021222885A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021264077A1 (en) | 2022-12-01 |
BR112022021831A2 (pt) | 2022-12-13 |
JP2023526776A (ja) | 2023-06-23 |
EP4142693A1 (en) | 2023-03-08 |
CA3177297A1 (en) | 2021-11-04 |
CN115484930A (zh) | 2022-12-16 |
US20230210762A1 (en) | 2023-07-06 |
IL297669A (en) | 2022-12-01 |
WO2021222885A1 (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013698A (es) | Dispositivos de administracion transdermica de farmacos que contienen psilocibina, dietilamida de acido lisergico o microprotuberancias recubiertas con 3,4-metilendioximetanfetamina. | |
MX2023009610A (es) | Esteroides neuroactivos, y su metodo de uso. | |
BR112015024869A8 (pt) | uso de um agente terapêutico e/ou de diôxido de carbono para tratar um paciente e aparelhos e métodos para tratar terapeuticamente um paciente | |
ZA202103404B (en) | Composition and method for treating the lungs | |
MX2020013607A (es) | Sistemas y métodos para acceder a senos. | |
MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
MX2019011491A (es) | Formulaciones de niraparib. | |
MX2022009736A (es) | Compuestos y metodos de p2x3 y/o p2x2/3. | |
MX2023000314A (es) | Formulaciones farmaceuticas transdermicas de cannabinoides. | |
MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
Kaur et al. | Comparative study between dexamethasone and dexmedetomidine in supraclavicular block | |
EA201990419A1 (ru) | Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение | |
MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
MX2021009082A (es) | Compuestos quimicos. | |
Jadon et al. | Serratus anterior plane block failed to relieve pain in multiple fractured ribs: report of two cases | |
MX2019004879A (es) | Materiales y metodos para el control de biopeliculas. | |
MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
MX2022002152A (es) | Agonistas biciclicos del estimulador de genes de interferon sting. | |
Rao et al. | A randomised double blind prospective study to compare clonidine and dexmedetomidine as an adjuvant in supra-clavicular brachial plexus block | |
MX2021008329A (es) | Farmaco profilactico o terapeutico para enfermedades neurodegenerativas. | |
Jadon | Serratus Anterior Plane Block for Pain Relief in Multiple Fractured Ribs (Mfrs); Injection of Local Anaesthetic above the Serratus or below the Serratus?-A Case Report | |
BR112022004535A2 (pt) | Formulações de entrega de fármaco | |
Bansal et al. | Supraclavicular brachial plexus block: effect of using dexmedetomidine as adjuvant to ropivacaine. A randomized double blind study | |
MX2018012439A (es) | Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico. | |
Sushma et al. | A clinical study of effects of 30 ml of 1.5% lidocaine with adrenaline and 30 ml of 0.333% levobupivacaine for axillary block using nerve stimulation technique |